Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate-release oral formulation in healthy volunteers

Ralinepag (APD811), an oral, potent, and selective prostacyclin receptor (IP) agonist is being developed for treatment of pulmonary arterial hypertension. Two, single-center, randomized, double-blind, placebo-controlled, Phase 1 studies (single ascending dose and multiple ascending dose) evaluated a...

Descripción completa

Detalles Bibliográficos
Autores principales: Grundy, John S., King, Christopher D., Adams, John W., Cabell, Christopher H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238799/
https://www.ncbi.nlm.nih.gov/pubmed/32489643
http://dx.doi.org/10.1177/2045894020922814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238799/
https://www.ncbi.nlm.nih.gov/pubmed/32489643
http://dx.doi.org/10.1177/2045894020922814

Ejemplares similares